ArticleExperimental and molecular pathology2026
Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
Article in Experimental and molecular pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CXCL1-CXCR2 axis inhibits melanogenesis through the suppression of the WNT/β-catenin pathway.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The CXCR2-CXCL1 axis is critical in tumorigenesis, specifically, CXCL1 is a secreted chemokine implicated in tumor progression, angiogenesis, and immune modulation. Although elevated CXCL1 expression has been associated with poor outcomes in cancers, its evaluation by immunohistochemistry (IHC) is limited by diffusion and stromal expression. We developed a qPCR-based assay to objectively quantify CXCL1 mRNA in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. We analytically validated the CXCL1 qPCR assay using FFPE tissues from muscle-invasive bladder cancer (MIBC) patients. Assay performance was evaluated across preanalytical (tissue preparation, storage conditions), analytical (RNA input, quality, necrosis), and reproducibility parameters. The assay was then applied to a cohort of 47 MIBC patients who underwent radical cystectomy after neoadjuvant chemotherapy, and qPCR expression values were validated against RNA-seq TPM. The assay showed high concordance between fresh frozen and FFPE tissues (P = 0.78), stable RNA profiles under appropriate storage, and robust performance across a 5-100 ng input range when RNA DV200 exceeded 15%. Expression remained reliable in samples with up to 80% necrosis. Inter-operator reproducibility was strong (Pearson r = 0.80). In the clinical cohort, CXCL1 expression by qPCR showed excellent agreement with RNA-seq expression in 47 MIBC patients (Pearson r = 0.88), confirming the assay's robustness and cross-platform validity. We present a robust, analytically validated qPCR assay for quantifying CXCL1 expression in FFPE tumor specimens. The assay demonstrated excellent concordance with RNA-seq expression values, supporting its reliability for measuring CXCL1 mRNA expression in bulk tumor specimens and its potential utility as a companion diagnostic in future CXCR-2-CXCL1-targeted clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.